**Question:** All of the following are irreversible ADP inhibitors except

A. AraC (Cytosine arabinoside)
B. Fludarabine
C. Idarubicin
D. Daunorubicin

**Correct Answer: A. AraC (Cytosine arabinoside)**

**Core Concept:**

Inhibition of purine synthesis is a therapeutic strategy in cancer treatment. ADP (Adenosine Diphosphate) is a crucial molecule involved in various cellular processes, including energy production and DNA synthesis. Some anticancer agents target enzymes involved in purine synthesis, leading to cell death.

**Why the Correct Answer is Right:**

AraC (Cytosine arabinoside) is an example of an analogue of hypoxanthine-guanine phosphoribosyl-transerase (HPRT), an enzyme involved in purine synthesis. Unlike other options, AraC is a substrate for HPRT and gets incorporated into DNA, leading to cell death due to DNA damage. This makes AraC a competitive inhibitor of HPRT and hence a reversible inhibitor.

**Why Each Wrong Option is Incorrect:**

B. Fludarabine: Fludarabine is a purine analogue acting as a competitive inhibitor of HPRT, similar to AraC. However, it is converted to its active form, fludarabine phosphate, which is an inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in guanine synthesis. Fludarabine is not an inhibitor of HPRT, making it an irreversible inhibitor.

C. Idarubicin: Idarubicin is a daunosine analogue that intercalates into DNA and causes cross-linking of DNA strands, leading to cell death. This makes it an irreversible inhibitor, distinct from AraC which is a competitive inhibitor.

D. Daunorubicin: Daunorubicin is a daunosine analogue that intercalates into DNA and causes cross-linking of DNA strands, leading to cell death. Like idarubicin, daunorubicin is an irreversible inhibitor.

**Clinical Pearl:**

The distinction between reversible and irreversible inhibitors is crucial when considering the mode of action and potential side effects of chemotherapeutic agents. Reversible inhibitors, like AraC, allow the enzyme to recover after drug removal, reducing the risk of long-term toxicity. On the other hand, irreversible inhibitors, such as idarubicin and daunorubicin, cause long-lasting disruption of cellular processes, increasing the risk of side effects. However, they also target cancer cells more effectively due to their mechanism of action.